_id
6915f910bc934aba376b2601
Ticker
SION
Name
Sionna Therapeutics, Inc. Common Stock
Exchange
NASDAQ
Address
21 Hickory Drive, Waltham, MA, United States, 02451
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.sionnatx.com
Description
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Last Close
40.39
Volume
261226
Current Price
39.11
Change
-3.63
Last Updated
2026-01-07T11:48:16.848Z
Image
data:image/webp;base64,UklGRjAEAABXRUJQVlA4WAoAAAAQAAAAPwAAPwAAQUxQSIICAAABoLJte+PKndbHt4mYCxvNNmxtSzEacrAHLzoNpVnUaNtgKz0RsUgqEkkz2t6QiNE2EaMhL/CMmhMRE0DpWX3Hot9ZKah0oRDrlSiJGSR1TTGVR2rLy6g80vu6BO6RsynBIqenAgVCjRRCHN6xAXdKUAGG03Bt+ngJfshSOFcADJWI4TqCqHqIuoQqgBIeUokioEpQaIDZFz8Ew/dDBQDmsNoDEbRrpWBlkYnZfagaVhBzCXYVL4bYwzTAHVYK0Z1EcFUxxFUa+KoYItYolwCuoF1WSxsDWVZvdWiC3B4QEVcBqPaC6DCg2RNyQ7IAVSWxBQngDkvgClIAvOQxhxgW2Rj6TcMDmEQgy3Y4AMAZKQ9FIw1CDWV3IWlFthqZFWWvXJ6HLB+xOzkMoyK5SuVqKpYd2gQPGypcSGOHnDms6P+f79NottC789nVbNNxkoO/Nh0AvNk8s/p0koW3lPL0DYI36+9v82R8OUnxWefv1KKW1vcA2PzVTkdJri4XFC9vdZJRf626HqB7/ctiOoo5M9N6HFc5JyiUzbc9AN6sdXt7wodGB0utZxTN/WFFkaP5mz6ge/2L1rqd7y611npB0eyhZxQ/Vm/6ALxZr3Tg4kwUfwhJSae/vBkAOvfXwOIMxdYejqWhM6fWDwDoNutftD6gWG4A1JT86nK9Hdrd/iUFD6oVAFjKeGamH3Yh/Q+tklJK8xC9nucgGrerZ11MdE2Zzxzo1bMuR0P5+VyvnnXJGipyutSrZ10SX1Oho7nWq/U2znIqd9xqra3rgqwgojPjybgMokmrtdZ/vX7TAdi+efan7l/wUogmc51wOaGiR7M2YjGh8vn0tO1ZzqechgFWUDggiAEAANAKAJ0BKkAAQAA+pUKYSaYkIqE39q34wBSJbAhwAYu5G7M8MMxfB+uPol6gNtnz2/pQ/4HpgdQBvJzo3GT8SnDvm++PXbDhgzm1gFdMaU5M6EP86hVvz1C5PeSYKKjAAP7NdM/2EjggzDwQv1B7QaJ7paK0Rtfo1lNKyLVXFCOsItoAa5lXjpRxc/XCY68WQhPRLTjJNIytiw13HMndTf3chiWfSY3Dqxvp/o1u556JJkeXkkA+KQmdjkqfHn1O1Yjr0Y4WN8aEu1UAaS3RWE1Cp706gnK4SUyM+BBOVRjQ1j4ZQ/YJDHnmeYwQhpfaqLBdkg6Uoin/0p5pVhGm2ya4P7n/gf5V//8AQ5sSBpug0tM/9of/vP7//BsEKnebvPY8CAwO2jgWImFxIlBBzNpP1lqVXhgC1Q8W12VSpVzv/S6X0YCZRtrzwGXbAS8XNsQjBUku8fwAcRT1odDndIaHWAORX6Pm9hHHg66XAhh3QcH5ePyeRDRFgsGIcyBbvY1v4tCQz4AA
Ipo Date
2025-02-07T00:00:00.000Z
Market Cap
1823085952
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.94525
Sentiment Sources
4
Rating
5
Target Price
45.75
Strong Buy
3
Buy
0
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
100000
Gross Profit
-100000
Operating Expenses
23705000
Operating Income
-23805000
Interest Expense
-
Pretax Income
-20278000
Net Income
-20278000
Eps
-0.456059187567374
Dividends Per Share
-
Shares Outstanding
44628788
Income Tax Expense
-
EBITDA
-20178000
Operating Margin
-
Total Other Income Expense Net
3527000
Cash
50831000
Short Term Investments
197498000
Receivables
-
Inventories
-
Total Current Assets
252328000
Property Plant Equipment
9309000
Total Assets
339270000
Payables
1481000
Short Term Debt
1217000
Long Term Debt
-
Total Liabilities
17602000
Equity
321668000
Bs_currency_symbol
USD
Depreciation
100000
Change In Working Capital
1899000
Cash From Operations
-15230000
Capital Expenditures
87000
Cash From Investing
23102000
Cash From Financing
1974000
Net Change In Cash
9846000
Cf_currency_symbol
USD
PE
-
PB
5.406097407793129
ROE
-6.30401532014375
ROA
-5.976950511392107
FCF
-15317000
Fcf Percent
-
Piotroski FScore
1
Health Score
38
Deep Value Investing Score
3
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
3
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
100000
Quarters > 0 > income Statement > gross Profit
-100000
Quarters > 0 > income Statement > operating Expenses
23705000
Quarters > 0 > income Statement > operating Income
-23805000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-20278000
Quarters > 0 > income Statement > net Income
-20278000
Quarters > 0 > income Statement > eps
-0.456059187567374
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
44463527
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-20178000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
3527000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
50831000
Quarters > 0 > balance Sheet > short Term Investments
197498000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
252328000
Quarters > 0 > balance Sheet > property Plant Equipment
9309000
Quarters > 0 > balance Sheet > total Assets
339270000
Quarters > 0 > balance Sheet > payables
1481000
Quarters > 0 > balance Sheet > short Term Debt
1217000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
17602000
Quarters > 0 > balance Sheet > equity
321668000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-20278000
Quarters > 0 > cash Flow > depreciation
100000
Quarters > 0 > cash Flow > change In Working Capital
1899000
Quarters > 0 > cash Flow > cash From Operations
-15230000
Quarters > 0 > cash Flow > capital Expenditures
87000
Quarters > 0 > cash Flow > cash From Investing
23102000
Quarters > 0 > cash Flow > cash From Financing
1974000
Quarters > 0 > cash Flow > net Change In Cash
9846000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.456059187567374
Quarters > 0 > ratios > PB
5.406097407793129
Quarters > 0 > ratios > ROE
-6.30401532014375
Quarters > 0 > ratios > ROA
-5.976950511392107
Quarters > 0 > ratios > FCF
-15317000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
38
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
147000
Quarters > 1 > income Statement > gross Profit
-147000
Quarters > 1 > income Statement > operating Expenses
21759000
Quarters > 1 > income Statement > operating Income
-21906000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-18068000
Quarters > 1 > income Statement > net Income
-18068000
Quarters > 1 > income Statement > eps
-0.40940500365061105
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
44132338
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-17921000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
3838000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
40985000
Quarters > 1 > balance Sheet > short Term Investments
221586000
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
266746000
Quarters > 1 > balance Sheet > property Plant Equipment
9641000
Quarters > 1 > balance Sheet > total Assets
352048000
Quarters > 1 > balance Sheet > payables
914000
Quarters > 1 > balance Sheet > short Term Debt
1168000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
15619000
Quarters > 1 > balance Sheet > equity
336429000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-18068000
Quarters > 1 > cash Flow > depreciation
147000
Quarters > 1 > cash Flow > change In Working Capital
-2396000
Quarters > 1 > cash Flow > cash From Operations
-18153000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-23245000
Quarters > 1 > cash Flow > cash From Financing
-312000
Quarters > 1 > cash Flow > net Change In Cash
-41710000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.40940500365061105
Quarters > 1 > ratios > PB
5.130401181764949
Quarters > 1 > ratios > ROE
-5.3705239441308565
Quarters > 1 > ratios > ROA
-5.132254692541926
Quarters > 1 > ratios > FCF
-18153000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
37
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
19659000
Quarters > 2 > income Statement > operating Income
-19659000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-16482000
Quarters > 2 > income Statement > net Income
-16482000
Quarters > 2 > income Statement > eps
-0.373808315894653
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
44092117
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-19228000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
3177000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
82695000
Quarters > 2 > balance Sheet > short Term Investments
186971000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
273680000
Quarters > 2 > balance Sheet > property Plant Equipment
10010000
Quarters > 2 > balance Sheet > total Assets
369674000
Quarters > 2 > balance Sheet > payables
5019000
Quarters > 2 > balance Sheet > short Term Debt
1119000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
17905000
Quarters > 2 > balance Sheet > equity
351769000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-16482000
Quarters > 2 > cash Flow > depreciation
159000
Quarters > 2 > cash Flow > change In Working Capital
-1853000
Quarters > 2 > cash Flow > cash From Operations
-16288000
Quarters > 2 > cash Flow > capital Expenditures
86000
Quarters > 2 > cash Flow > cash From Investing
-141194000
Quarters > 2 > cash Flow > cash From Financing
202389000
Quarters > 2 > cash Flow > net Change In Cash
44907000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.373808315894653
Quarters > 2 > ratios > PB
4.9022020015123555
Quarters > 2 > ratios > ROE
-4.685461197547254
Quarters > 2 > ratios > ROA
-4.4585229147843775
Quarters > 2 > ratios > FCF
-16374000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
38
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
18133000
Quarters > 3 > income Statement > operating Income
-18133000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-15848000
Quarters > 3 > income Statement > net Income
-15848000
Quarters > 3 > income Statement > eps
-0.35916640577545383
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
44124394
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-17966000
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
2285000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
37788000
Quarters > 3 > balance Sheet > short Term Investments
109750000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
150993000
Quarters > 3 > balance Sheet > property Plant Equipment
10298000
Quarters > 3 > balance Sheet > total Assets
185752000
Quarters > 3 > balance Sheet > payables
1186000
Quarters > 3 > balance Sheet > short Term Debt
1072000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
349465000
Quarters > 3 > balance Sheet > equity
-163713000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-15848000
Quarters > 3 > cash Flow > depreciation
167000
Quarters > 3 > cash Flow > change In Working Capital
3136000
Quarters > 3 > cash Flow > cash From Operations
-11781000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
15228000
Quarters > 3 > cash Flow > cash From Financing
-1408000
Quarters > 3 > cash Flow > net Change In Cash
2039000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.35916640577545383
Quarters > 3 > ratios > PB
-10.541038581786419
Quarters > 3 > ratios > ROE
9.680355255844068
Quarters > 3 > ratios > ROA
-8.531805848658426
Quarters > 3 > ratios > FCF
-11781000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
31
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
668000
Annuals > 0 > income Statement > gross Profit
-668000
Annuals > 0 > income Statement > operating Expenses
69888000
Annuals > 0 > income Statement > operating Income
-70556000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-61688000
Annuals > 0 > income Statement > net Income
-61688000
Annuals > 0 > income Statement > eps
-1.3980475289926928
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
44124394
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-69888000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
8868000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
37788000
Annuals > 0 > balance Sheet > short Term Investments
109750000
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
150993000
Annuals > 0 > balance Sheet > property Plant Equipment
10298000
Annuals > 0 > balance Sheet > total Assets
185752000
Annuals > 0 > balance Sheet > payables
1186000
Annuals > 0 > balance Sheet > short Term Debt
1072000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
349465000
Annuals > 0 > balance Sheet > equity
-163713000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-61688000
Annuals > 0 > cash Flow > depreciation
668000
Annuals > 0 > cash Flow > change In Working Capital
-3075000
Annuals > 0 > cash Flow > cash From Operations
-52787000
Annuals > 0 > cash Flow > capital Expenditures
27000
Annuals > 0 > cash Flow > cash From Investing
-126913000
Annuals > 0 > cash Flow > cash From Financing
178967000
Annuals > 0 > cash Flow > net Change In Cash
-733000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-1.3980475289926928
Annuals > 0 > ratios > PB
-10.031640399235247
Annuals > 0 > ratios > ROE
37.680575152858964
Annuals > 0 > ratios > ROA
-33.209871226150995
Annuals > 0 > ratios > FCF
-52814000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
30
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
50333000
Annuals > 1 > income Statement > operating Income
-50333000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-47263000
Annuals > 1 > income Statement > net Income
-47263000
Annuals > 1 > income Statement > eps
-1.0711308579104792
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
44124394
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-49750000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
3070000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
38521000
Annuals > 1 > balance Sheet > short Term Investments
0
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
39207000
Annuals > 1 > balance Sheet > property Plant Equipment
11732000
Annuals > 1 > balance Sheet > total Assets
51945000
Annuals > 1 > balance Sheet > payables
719000
Annuals > 1 > balance Sheet > short Term Debt
728000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
166826000
Annuals > 1 > balance Sheet > equity
-114881000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-47263000
Annuals > 1 > cash Flow > depreciation
583000
Annuals > 1 > cash Flow > change In Working Capital
-783000
Annuals > 1 > cash Flow > cash From Operations
-43699000
Annuals > 1 > cash Flow > capital Expenditures
1116000
Annuals > 1 > cash Flow > cash From Investing
27352000
Annuals > 1 > cash Flow > cash From Financing
31000
Annuals > 1 > cash Flow > net Change In Cash
-16316000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-1.0711308579104792
Annuals > 1 > ratios > PB
-14.295749033173458
Annuals > 1 > ratios > ROE
41.14083268773774
Annuals > 1 > ratios > ROA
-90.98662046395226
Annuals > 1 > ratios > FCF
-44815000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
41372000
Annuals > 2 > income Statement > operating Income
-41372000
Annuals > 2 > income Statement > interest Expense
-
Annuals > 2 > income Statement > pretax Income
-40240000
Annuals > 2 > income Statement > net Income
-40240000
Annuals > 2 > income Statement > eps
-0.9119671989149585
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
44124394
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-41250000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
1132000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
54837000
Annuals > 2 > balance Sheet > short Term Investments
27773000
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
83833000
Annuals > 2 > balance Sheet > property Plant Equipment
2574000
Annuals > 2 > balance Sheet > total Assets
87369000
Annuals > 2 > balance Sheet > payables
557000
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
157293000
Annuals > 2 > balance Sheet > equity
-69924000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-40240000
Annuals > 2 > cash Flow > depreciation
122000
Annuals > 2 > cash Flow > change In Working Capital
2764000
Annuals > 2 > cash Flow > cash From Operations
-36068000
Annuals > 2 > cash Flow > capital Expenditures
1874000
Annuals > 2 > cash Flow > cash From Investing
-29263000
Annuals > 2 > cash Flow > cash From Financing
110855000
Annuals > 2 > cash Flow > net Change In Cash
45524000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.9119671989149585
Annuals > 2 > ratios > PB
-23.487070886676964
Annuals > 2 > ratios > ROE
57.54819518334191
Annuals > 2 > ratios > ROA
-46.057526124826886
Annuals > 2 > ratios > FCF
-37942000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
30
Valuation > metrics > PE
-0.456059187567374
Valuation > metrics > PB
5.406097407793129
Valuation > final Score
25.93902592206871
Valuation > verdict
80.2% Overvalued
Profitability > metrics > ROE
-6.30401532014375
Profitability > metrics > ROA
-8.036365365714467
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.05472101670044891
Risk > metrics > Interest Coverage
-238.05
Risk > final Score
-892
Risk > verdict
High
Liquidity > metrics > Current Ratio
93.5240919199407
Liquidity > metrics > Quick Ratio
93.5240919199407
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
28.69598818235051
Prev Valuations > 1
30.977979984876445
Prev Valuations > 2
50
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
34
Prev Risks > 0
-536
Prev Risks > 1
31
Prev Risks > 2
-4
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:34:20.184Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-05
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.46
Earnings History > 0 > eps Estimate
-0.6
Earnings History > 0 > eps Difference
0.14
Earnings History > 0 > surprise Percent
23.3333
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-11
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.41
Earnings History > 1 > eps Estimate
-0.52
Earnings History > 1 > eps Difference
0.11
Earnings History > 1 > surprise Percent
21.1538
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-13
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.62
Earnings History > 2 > eps Estimate
-0.45
Earnings History > 2 > eps Difference
-0.17
Earnings History > 2 > surprise Percent
-37.7778
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-03-20
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-3.38
Earnings History > 3 > eps Estimate
-2.68
Earnings History > 3 > eps Difference
-0.7
Earnings History > 3 > surprise Percent
-26.1194
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ABTIG Research Reiterates Buy Rating for Sionna Therapeutics (NASDAQ:SION) MarketBeat
Read more →Assessing Sionna Therapeutics (SION) Valuation After Recent Share Price Swings And Premium P/B Multiple Yahoo Finance
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$45.75
Analyst Picks
Strong Buy
3
Buy
0
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Sionna Therapeutics, Inc. Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.46
EPS Estimate
-0.6
EPS Difference
0.14
Surprise Percent
23.3333%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.